Amylin Pharmaceuticals – New Version of Byetta


Amylin Pharmaceuticals Inc expects is new longer acting version of Byetta to be available this year.  The drug is called once-weekly exenatide and is being developed by Amylin and Eli Lilly & Co.

A new competitor of Byetta – Novo Nordisk’s Victoza, was approved by the FDA recently and that has given analysts more confidence in the approval of Exenatide.

The new once weekly exenatide is an injectable drug that lasts for a full week and has had impressive results in trials.

 

Source: Reuters


About Andy

Andy writes for a number of health related sites but has always been fascinated by alternative medicine and home remedies. His deep interests in nature and the body's innate ability to heal itself (given the right condition) have lead him to a pivotal time in his life - and so, Holistic Home Fitness was born. While it's relatively new at the moment, Andy wants to build this site into a huge reference site for a more holistic approach to health and fitness.